Bayer Aims to Expand Xarelto Use Despite Known Risks, Rottenstein Law Group LLP Notes with Concern

Rockville Centre, NY -- (SBWIRE) -- 08/29/2014 -- According to a Reuters report, Xarelto manufacturer Bayer is going to be testing the drug—currently very popular as a treatment for preventing strokes—on patients with “embolic stroke of undetermined source and peripheral artery disease” and for long-term prevention in patients who have suffered an acute coronary syndrome.”*